# Vancomycin Hydrochloride (vancomycin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vancomycin

> The FDA approved Vancomycin Hydrochloride (vancomycin), sponsored by Viatris Inc (VTRS), on July 10, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vancomycin Hydrochloride (vancomycin) |
| Codes |  |
| Sponsor | Viatris Inc (VTRS) https://sec-api.dev/companies/vtrs/catalysts |
| Indications | high-risk of cdi |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 10, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209481 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180710, review_priority STANDARD; sponsor_name MYLAN LABS LTD; product VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209481%22

### Mar 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1/2.
- First seen 2025-05-19, last confirmed 2025-05-19.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-050219): "Positive topline results from Phase 1b/2a trial ("SWARM-Pa") of inhaled AP-PA02 in patients with CF announced March 2023" https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_ex99-2.htm

### June 26, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209481 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20240626, review_priority N/A; sponsor_name MYLAN LABS LTD; product VANCOMYCIN HYDROCHLORIDE (VANCOMYCIN HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209481%22

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: high-risk of CDI.
- First seen 2025-02-28, last confirmed 2025-02-28.
- SEC Form 10-K (accession 0001601830-25-000035): "In October 2024, we initiated a Phase 2 open-label, randomized, 3-arm study (ALDER) to evaluate the rate of recurrence in patients with a high-risk of CDI, who have achieved symptom resolution following treatment with oral vancomycin for 14 days." https://www.sec.gov/Archives/edgar/data/1601830/000160183025000035/rxrx-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vancomycin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vancomycin Hydrochloride (vancomycin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vancomycin

```bibtex
@misc{secapidev_pdufa_vancomycin_20261116,
  title        = {Vancomycin Hydrochloride (vancomycin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vancomycin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vancomycin_20261116","title":"Vancomycin Hydrochloride (vancomycin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vancomycin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
